Title:
FACTOR XI ANTIBODIES AND METHODS OF USE
Document Type and Number:
Japanese Patent JP2022116069
Kind Code:
A
Abstract:
To provide safer therapies which can reduce AF thromboembolic complications such as stroke, systemic embolism, cognitive decline and mortality with comparable efficacy as existing therapy but with a lower bleeding liability.SOLUTION: Provided are monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI ("Factor XIa"), and pharmaceutical compositions and methods of treatment comprising the same.SELECTED DRAWING: None
More Like This:
| WO/1995/017085 | TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK |
| JP6363255 | Antibodies to human EPO receptors |
| JP2005531282 | Anti-TIRC7 antibody used to treat inflammatory diseases |
Inventors:
JORG EDER
STEFAN EWERT
ULRICH HASSIEPEN
YASSER KHDER
LORENZ M MAYR
SAMU MELKKO
NIKOLAUS SCHIERING
STEFAN EWERT
ULRICH HASSIEPEN
YASSER KHDER
LORENZ M MAYR
SAMU MELKKO
NIKOLAUS SCHIERING
Application Number:
JP2022079828A
Publication Date:
August 09, 2022
Filing Date:
May 13, 2022
Export Citation:
Assignee:
NOVARTIS AG
International Classes:
C12N15/13; A61K39/395; A61K45/00; A61P7/02; A61P9/00; A61P9/10; A61P25/00; C07K16/36; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63
Attorney, Agent or Firm:
Hiroshi Kobayashi
Eiji Katayama
Norio Omori
Ryo Hoshikawa
Eiji Katayama
Norio Omori
Ryo Hoshikawa
Previous Patent: can lids and beverage cans
Next Patent: Display device and manufacturing method thereof
Next Patent: Display device and manufacturing method thereof